Janus Henderson Group PLC Avadel Pharmaceuticals PLC Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.55 - $17.22 $22.5 Million - $30.8 Million	1,789,830 Added 16.09%	12,915,160 $218 Million
Q4 2023 Feb 14, 2024	BUY	$9.64 - $14.59 $4.69 Million - $7.11 Million	487,023 Added 4.58%	11,125,330 $157 Million
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $32.1 Million - $49.8 Million	3,115,762 Added 41.42%	10,638,307 $110 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $5.9 Million - $11.5 Million	695,758 Added 10.19%	7,522,545 $124 Million
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $36 Million - $55.9 Million	5,619,257 Added 465.35%	6,826,787 $62.5 Million
Q4 2022 Feb 14, 2023	BUY	$5.02 - $10.0 $6.06 Million - $12.1 Million	1,207,530 New	1,207,530 $8.65 Million
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $1.51 Million - $9.8 Million	-1,410,387 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $2.22 Million - $3.37 Million	407,069 Added 40.57%	1,410,387 $9.63 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $1.41 Million - $2.15 Million	192,061 Added 23.67%	1,003,318 $8.12 Million
Q3 2021 Nov 16, 2021	BUY	$6.49 - $9.91 $444,467 - $678,686	68,485 Added 9.22%	811,257 $7.94 Million
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $3.29 Million - $4.43 Million	489,545 Added 193.32%	742,772 $5 Million
Q1 2021 May 17, 2021	BUY	$6.61 - $10.07 $157,483 - $239,917	23,825 Added 10.39%	253,227 $2.3 Million
Q4 2020 Feb 16, 2021	BUY	$5.03 - $7.95 $1.15 Million - $1.82 Million	229,402 New	229,402 $1.54 Million
Q4 2017 Feb 09, 2018	SELL	$8.03 - $11.25 $17.3 Million - $24.2 Million	-2,154,082 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$8.35 - $10.5 $257,422 - $323,704	-30,829 Reduced 1.41%	2,154,082 $0
Q2 2017 Aug 17, 2017	BUY	N/A	2,184,911	2,184,911 $24.1 Million

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account